Back to ARNA Stock Lookup

Arena Pharma (ARNA) – Company Press Releases

Oct 21, 2021 04:05 PM Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 14, 2021 04:05 PM Arena Pharmaceuticals to Release Third Quarter 2021 Financial Results and Provide Corporate Update on November 4
Sep 21, 2021 08:30 AM Longboard Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference on September 28, 2021
Sep 17, 2021 04:05 PM Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 8, 2021 07:00 AM Longboard Pharmaceuticals Successfully Completes LP352 Multiple Ascending Dose Portion of Phase 1 Clinical Trial in Healthy Volunteers, Plans to Initiate Phase 1b/2a Clinical Trial
Sep 2, 2021 08:30 AM Arena Pharmaceuticals to Host Virtual R&D Investor Calls and Participate in Upcoming September Investor Conferences
Aug 31, 2021 08:30 AM Longboard Pharmaceuticals to Present at Two Upcoming Investor Conferences
Aug 18, 2021 04:05 PM Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 9, 2021 08:30 AM Longboard Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2021 Financial Results
Aug 5, 2021 04:05 PM Arena Reports Second Quarter Financial Results and Key Program Updates
Aug 5, 2021 07:00 AM Second Genome Announces Collaboration with Arena Pharmaceuticals to Identify Gastrointestinal Biomarkers
Jul 29, 2021 04:05 PM Arena Pharmaceuticals to Release Second Quarter 2021 Financial Results and Provide Corporate Update on August 5
Jul 27, 2021 04:05 PM Arena Pharmaceuticals and Aristea Therapeutics Establish Collaboration for Development of RIST4721 for Treatment of Serious Immune-Mediated Inflammatory Diseases
Jul 22, 2021 04:05 PM Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jul 19, 2021 08:30 AM Arena Pharmaceuticals Appoints Doug Manion, M.D., F.R.C.P. (C), as Executive Vice President of Research & Development
Jun 18, 2021 04:05 PM Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 14, 2021 08:30 AM Steven Schoch Elected to Arena Pharmaceuticals Board of Directors
Jun 9, 2021 08:43 AM Arena Pharmaceuticals Announces Orphan Drug Designation for Etrasimod for the Treatment of Eosinophilic Esophagitis (EoE)
Jun 8, 2021 08:30 AM Arena Pharmaceuticals Announces First Participant Randomized in Phase 2 Trial Evaluating Temanogrel in Coronary Microvascular Obstruction (cMVO)
Jun 3, 2021 08:30 AM Arena Pharmaceuticals Earns "A" Rating from MSCI ESG, a Leading Rating Agency for Sustainable Investments
May 19, 2021 05:30 PM Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 12, 2021 08:30 AM Arena Pharmaceuticals Earns Prime Status from ISS ESG, a Leading Rating Agency for Sustainable Investments
May 10, 2021 04:05 PM Longboard Pharmaceuticals Provides Corporate Update and Reports First Quarter 2021 Financial Results
May 5, 2021 04:05 PM Arena Reports First Quarter Financial Results with Strong Cash Position and Continued Progress on Pipeline Over the Quarter
Apr 28, 2021 04:05 PM Arena Pharmaceuticals to Release First Quarter 2021 Financial Results and Provide Corporate Update on May 5
Apr 23, 2021 10:10 AM Arena Pharmaceuticals Presents Clinician and Patient Reported Outcomes Data from Phase 2b ADVISE Trial Evaluating Etrasimod in Adult Atopic Dermatitis During a Late-Breaking Session at American Academ
Apr 19, 2021 04:05 PM Arena Pharmaceuticals Releases Second Annual Environmental, Social and Governance (ESG) Report
Apr 19, 2021 08:30 AM Arena Pharmaceuticals to Present Data from the Phase 2b ADVISE Trial During Late-Breaking Research Session at American Academy of Dermatology Virtual Meeting Experience
Apr 16, 2021 06:35 PM Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 19, 2021 08:30 AM Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 11, 2021 09:44 PM Longboard Pharmaceuticals Announces Pricing of Initial Public Offering
Mar 2, 2021 04:05 PM Arena Pharmaceuticals Reports Topline Results from Phase 2b CAPTIVATE Clinical Trial
Feb 23, 2021 04:05 PM Arena Reports Fourth Quarter Financial Results with Strong Liquidity Position and Maintained Pipeline Progress Over the Quarter
Feb 18, 2021 04:05 PM Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 16, 2021 04:05 PM Arena Pharmaceuticals to Release Fourth Quarter & Full-Year 2020 Financial Results and Provide Corporate Update on February 23
Feb 16, 2021 08:30 AM Arena Pharmaceuticals Announces Changes to Board of Directors
Feb 2, 2021 09:05 AM Arena Pharmaceuticals Completes Full Enrollment of Etrasimod Phase 3 ELEVATE UC 52 Trial
Jan 22, 2021 04:04 PM Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 22, 2020 04:01 PM Arena Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference on January 13
Dec 18, 2020 01:01 PM Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 11, 2020 09:00 AM Arena Pharmaceuticals to Present Data from the Phase 2b ADVISE Trial - Late-Breaker at Revolutionizing Atopic Dermatitis Conference
Dec 8, 2020 08:30 AM Arena Pharmaceuticals Achieves Target Enrollment for Etrasimod Phase 3 ELEVATE UC 52 Trial
Nov 30, 2020 04:05 PM Arena Pharmaceuticals Announces R&D Leadership Transition
Nov 24, 2020 08:30 AM Arena Pharmaceuticals to Present at the Evercore ISI HealthCONx Conference on December 1
Nov 19, 2020 05:59 PM Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 9, 2020 04:05 PM Arena Reports Third Quarter Financial Results with Strong Cash Position, Advancing Etrasimod Into a Phase 3 Registrational Program in Atopic Dermatitis
Nov 9, 2020 04:01 PM Arena Pharmaceuticals Advancing Etrasimod Into Phase 3 Program in Atopic Dermatitis (AD), Reports Compelling Topline Results from Phase 2b ADVISE Trial
Nov 2, 2020 08:30 AM Arena Pharmaceuticals to Release Third Quarter 2020 Financial Results and Provide Corporate Update on November 9
Oct 28, 2020 08:30 AM Arena Pharmaceuticals Announces Launch of Longboard Pharmaceuticals With $56M Financing, Building a Novel Neuroscience Drug Development Company
Oct 20, 2020 04:01 PM Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Back to ARNA Stock Lookup